You are here

Regeneron

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

Endpoints

clinical trials

Flag link:

Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance

Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance

Endpoints

drug development

Flag link:

Regeneron Earnings, Revenue Top Views; Shares Down Slightly

Regeneron Earnings, Revenue Top Views; Shares Down Slightly

Investors Business Daily

Flag link:

Earnings Preview: What To Expect From Regeneron Pharmaceuticals on Thursday

Earnings Preview: What To Expect From Regeneron Pharmaceuticals on Thursday

Forbes

Flag link:

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Fierce Pharma

Flag link:

The top 15 highest-paid biopharma executives

The top 15 highest-paid biopharma executives

Fierce Pharma

Valeant Pharmaceuticals

Flag link:

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

Motley Fool

Clovis Oncology

Flag link:

Novartis trial results could spell trouble for Regeneron

Novartis trial results could spell trouble for Regeneron

Drug Delivery Business News

clinical trials

neovascular age-related macular degeneration

Flag link:

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Market Realist

Flag link:

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Endpoints

Flag link:

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Fierce Pharma

LDL cholesterol

Flag link:

Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick

Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick

Motley Fool

Flag link:

Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price

Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price

Fierce Pharma

rheumatoid arthritis

Flag link:

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Fierce Biotech

Vertex Pharmaceuticals

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Regeneron posts mixed Q1 results, Eylea growth slows

Regeneron posts mixed Q1 results, Eylea growth slows

Drug Delivery Business News

Flag link:

5 Big Drugmakers With Important Catalysts in May

5 Big Drugmakers With Important Catalysts in May

Motley Fool

nonacog beta pegol

Flag link:

Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

Market Realist

Flag link:

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

Endpoints

Leonard Schleifer

Flag link:

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Yahoo

Flag link: